Borgan F, et al. - Considering the experimental and epidemiological studies indicating that cannabinoid 1 receptor (CB1R) plays a part in the pathophysiology of psychosis, researchers conducted this cross-sectional case-control study of 58 males investigating if, in first-episode psychosis, the cannabinoid 1 receptor is changed without the confounds of cannabis use and illness chronicity. Male patients with first-episode psychosis who did not use cannabis, including patients who were antipsychotic naive or antipsychotic-free, had lower cannabinoid 1 receptor availability. Exploratory analyses revealed low cognitive functioning and higher symptom severity in correlation to larger reductions. These findings suggest the potential value of cannabinoid 1 receptor modulation as a target in treating psychotic disorders.